Anti-Hepatitis C Virus Activity of a Crude Extract from Longan (<i>Dimocarpus longan</i> Lour.) Leaves

• DOI: 10.7883/yoken.jjid.2015.107
• Publication Date: 2015-08-06T22:05:16Z
• Authors: Dadan Ramadhan Ap...; Chie Aoki; Sri Hartati; Muhammad Hanafi; Leonardus Broto S...; Ade Arsianti; Melva Louisa; Tjahjani Mirawati...; Beti Ernawati Dewi; Pratiwi Sudarmono; Amin Soebandrio; Hak Hotta
• Keywords: Telaprevir; NS3; Pegylated interferon; Combination therapy; Hepatitis C; Protease inhibitor (pharmacology)

Infection with hepatitis C virus (HCV) results in C, a disease characterized by chronic infection, cirrhosis, and hepatocellular carcinoma. Currently, the standard therapy is combination of pegylated interferon-α plus ribavirin NS3 protease inhibitors. Addition inhibitors to improves response rates; however, use also associated significant adverse effects an increase overall cost treatment. Therefore, there need develop safe inexpensive drugs for treatment HCV infections. In this study, we examined antiviral activity crude extract from Dimocarpus longan leaves against (genotype 2a strain JFH1). The D. (DL-CE) exhibited anti-HCV 50% effective concentration (EC50) 19.4 μg/ml without cytotoxicity. A time-of-addition study demonstrated that DL-CE has at both entry post-entry steps markedly blocks viral step through direct virucidal marginal inhibition virion assembly. Co-treatment cyclosporine A, immunosuppressant or telaprevir, inhibitor, resulted additive synergistic effects, respectively. Our findings suggest may be useful as add-on candidate treating